LV Only MPP With SyncAV

Heart Failure Clinical Trial

Official title:

Characterization of Acute and Long Term Response to Left Ventricle Only Pacing Combined With MultiPoint Pacing and SyncAV

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03567096
• Other study ID #: SJM-CIP-10231
• Status: Completed
• Phase: N/A
• Start date: October 9, 2018
• Est. completion date: September 30, 2023

Study information

• Verified date: January 2024
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical investigation is to evaluate the clinical benefits of left ventricle (LV) only pacing combined with automatic adjustment of AV timing (SyncAV) in patients receiving cardiac resynchronization therapy (CRT) after 6 months of therapy. This clinical investigation is a prospective, two-arm, randomized 1:1, multicenter feasibility study designed to evaluate the effectiveness of LV only with multipoint pacing (MPP) and SyncAV compared to bi-ventricular pacing with MPP and SyncAV. The clinical investigation will be conducted at approximately 7 centers in Europe and Canada. Approximately 120 subjects will be enrolled in the study. No site may enroll more than 33% of the total subjects. Data will be collected at enrollment, CRT implant procedure, hospital pre-discharge, one and 6 months post implant. Enrollment data collection will include demographics, cardiovascular history, medication, echocardiography measurements and quality of life questionnaire. CRT implant procedure data collection will include implanted system information and lead location. The electrical conduction recording procedure will include surface ECG and device IEGM recordings during various pacing configurations at implant or up to 45 days post implant. In patients who consent to invasive measurements (expected target of at least 80 patients), a hemodynamic recording procedure will include invasive hemodynamic measurements during various pacing configurations which may take place during device implant or up to 45 days post implant. Hospital pre-discharge data collection will take place within 3 days after the CRT implant, electrical conduction recordings visit or hemodynamic recordings visit and will include system information, surface ECG, and device IEGMs. In a subset of patients from selected centers that have access to this technology (expected 20 patients), non-invasive electrical activation data will be collected with body surface mapping within 45 days of the implant procedure. Patients will be randomized 1:1 to receive either biventricular pacing with multipoint pacing (MPP) or LV-only pacing with MPP at the one-month (± 15 days) visit. The 6-month (± 15 days) post randomization follow up visit will include surface ECG, IEGMs, echocardiographic parameters and quality of life questionnaire. Subjects participating in this clinical investigation will follow the hospital center standard of care from implant to 6 month follow up. The expected duration of enrollment is 1.5 year. The total duration of the clinical investigation is expected to be 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: September 30, 2023
• Est. primary completion date: February 24, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with approved indication for CRT scheduled to be implanted with an MPP-enabled ABT Quadripolar CRT pacing system, de novo or upgrade from non-CRT system
• Patient must be > 18 years of age, able to provide informed consent and willing to comply with study requirements
• Documented permanent left bundle branch block (LBBB)
• Intrinsic QRS duration = 150 ms
• Sinus (or atrial paced) rhythm with intact AV conduction with PR interval = 250 ms

Exclusion Criteria:

• Resting heart rate > 100 bpm
• AV Block (1st degree with PR> 250 ms, 2nd or 3rd degree)
• Documented persistent atrial tachycardia or atrial fibrillation at the moment of enrollment or patients not likely to remain in sinus (or atrial paced) rhythm for the duration of the study
• Patients scheduled for AV node ablation to treat paroxysmal atrial arrhythmias
• Recent (< 3 months) myocardial infarction, ablation, electrolyte imbalance, or any condition within the last 90 days that would contraindicate for CRT programming changes in the opinion of the investigator
• Women who are pregnant or plan to become pregnant during the study course

Related Conditions & MeSH terms

• Bundle-Branch Block
• Heart Failure
• Left Bundle-Branch Block

Intervention

Device:
• BiV pacing with MPP and SyncAV
This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
• LV only pacing with MPP and SyncAV
This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.

Locations

Country	Name	City	State
Canada	Montreal Heart Institute	Montreal
France	CHU Rennes	Rennes
Italy	Policlinico Casilino	Roma
United Kingdom	Queen Elizabeth Hospital	Birmingham
United Kingdom	St. Bartholomew's Hospital	London
United Kingdom	John Radcliffe Hospital	Oxford

Sponsors (2)

Lead Sponsor	Collaborator
Abbott Medical Devices	Abbott

Countries where clinical trial is conducted

Canada,  France,  Italy,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Hemodynamic response	Acute changes in LV dP/dtmax (measured with pressure wire, pressure-volume loop catheter or non-invasive system) resulting from various CRT and SyncAV pacing configurations (subset of patients consenting to invasive measurements	intraoperative
Other	Left Ventricle Electrical Activation	Acute changes in LV activation time resulting from various CRT and SyncAV pacing configurations (subset of patients undergoing body surface mapping).	intraoperative
Primary	Clinical response	Patient clinical response to LV only pacing with SyncAV optimization at six-month follow-up evaluated by the Packer clinical composite score.	up to 6 months
Secondary	Left Ventricle reverse remodeling	Patient reverse remodeling response to LV only pacing at six-month follow-up defined as end-systolic volume reduction >15%.	up to 6 months
Secondary	Electrical resynchronization	Acute changes in surface ECG QRS duration resulting from various CRT and SyncAV pacing configurations.	intraoperative